AUPH logo

AURINIA PHARMACEUTICALS INC

AUPHNASDAQ
🏆 #1948 by market capUS Equity
$410.91▼ $15.12 (−3.68%)
Simulated price
🔔
Track AUPH
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.12B
Small Cap
📈Revenue Growth (YoY)
+20.4%
Healthy
📊Gross Margin
90.4%
High
💵FCF Margin
55.7%
Strong
⚖️P/S Ratio
6.8x
Fair
Otter Score
92
Very Good
No chart data available for AUPH.

Trading Snapshot

Day Range
$409.10 – $417.33
52-Week Range
$10.34 – $19.25
Volume
$3.87B
Avg Volume
$3.42B
Shares Outstanding
128.6M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$283M
Last Q Revenue
$83M
P/E Ratio
7.0
P/S Ratio
6.8x
EPS (TTM)
$2.41
Dividend Yield
0.00%
Dilution (1yr)
−6.1%

Why Investors Own AUPH

  • ✓High-growth profile — revenue up +47.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 34% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AUPH logo

AURINIA PHARMACEUTICALS INC

AUPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$283M▲ +20.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.5%▲ +0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$105M▼ −2338.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$135M▲ +207.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
138.7M▼ −6.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▲ +$1M YoY
StockOtter · stockotter.space

About AURINIA PHARMACEUTICALS INC

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
92/100

Analyst Price Target

ⓘ
Average Target
$466.45
▲ +13.5% Upside
High Target$564.92
Low Target$360.61
Based on 28 analysts

Latest News & Updates

🚀
CNBC·2h ago

AURINIA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift AUPH price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

AURINIA PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.